{"id":8505,"date":"2024-04-18T03:07:47","date_gmt":"2024-04-18T03:07:47","guid":{"rendered":"https:\/\/economicherald.net\/?p=8505"},"modified":"2024-04-18T03:07:47","modified_gmt":"2024-04-18T03:07:47","slug":"asx-health-stocks-immutep-hooks-leading-research-firm-chdr-to-conduct-phase-1-drug-study","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=8505","title":{"rendered":"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study"},"content":{"rendered":"<p>\u00a0Immutep teams up with CHDR for landmark human study of IMP761 in autoimmune diseases<br \/>\nNext Science\u2019s XPERIENCE proven effective: study shows zero infection rate after surgeries<\/p>\n<p>\u00a0<\/p>\n<h2>Immutep to partner with CHDR on first human study of IMP761<\/h2>\n<p>Cancer and autoimmune diseases focused biotech, <strong><a href=\"https:\/\/stockhead.com.au\/company\/immutep-imm\/\">Immutep (ASX:IMM)<\/a><\/strong>, has partnered with the <strong>Centre for Human Drug Research (CHDR)<\/strong> in the Netherlands to study a new drug called<strong> IMP761<\/strong> in humans for the first time.<\/p>\n<p>Under the agreement, CHDR \u2013 a world-class institute in Leiden, the Netherlands, specialising in cutting-edge early-stage clinical drug research \u2013 will perform a first-in-human <strong>Phase 1 clinical study of IMP761.<\/strong><\/p>\n<p>IMP761 is a special antibody that aims to help the immune system work better by restoring balance to the system and address the underlying cause of many autoimmune diseases.<\/p>\n<p>Subject to the relevant ethic and regulatory approvals, the study will involve about 49 healthy volunteers.\u00a0It will test the safety and effects of different doses of IMP761 compared to a placebo.<\/p>\n<p>The study will use a unique method developed by CHDR \u2013 the keyhole<em> limpet haemocyanin (KLH) challenge model<\/em> \u2013 to see how well the drug works in changing the immune system\u2019s response.<\/p>\n<p>\u201cWe are excited to leverage CHDR\u2019s expertise in working with targeted immunotherapy candidates in the clinical setting to evaluate IMP761\u2019s potential in changing how autoimmune disorders are treated,\u201d said <strong>Immutep\u2019s chief scientific officer, Dr Fr\u00e9d\u00e9ric Triebel.<\/strong><\/p>\n<p>The healthcare industry is starting to notice immune checkpoint agonists like LAG-3, PD-1, and CTLA-4 more and more.<\/p>\n<p>These are special checkpoints because they can help treat autoimmune diseases. Prior research papers for instance have identified LAG-3 as a promising immunotherapy target for autoimmune disorders including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among others.<\/p>\n<p>\u00a0<\/p>\n<h2>Next Science\u2019s study published on respected journal<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/next-science-nxs\/\">Next Science (ASX:NXS)<\/a><\/strong> has published a study showing that its product, <strong>XPERIENCE,<\/strong> can help prevent infections after joint replacement surgeries in knees, hips, and shoulders.<\/p>\n<p>In November 2023, leading orthopaedic surgeon <strong>Dr Robert Harris<\/strong> shared the results of a study on <em>VuMedi<\/em>. It showed that XPERIENCE is effective in preventing infections after joint replacement surgeries.<\/p>\n<p>The retrospective study showed a zero per cent infection rate in a cohort of 423 patients up to 90 days post-surgery.<\/p>\n<p>The findings of this study have now been reviewed by other experts and published in the <strong>Journal of Orthopaedic Surgery.<\/strong><\/p>\n<p>\u201cThe publication of these findings \u00a0means the study will now receive broader recognition in the orthopaedic community, and adds to the growing body of clinical evidence that will support Next Science being able to challenge for standard of care in surgical irrigation,\u201d said <strong>CEO, I.V. Hall.<\/strong><\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-immutep-hooks-leading-research-firm-chdr-to-conduct-phase-1-drug-study\/\">ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u00a0Immutep teams up with CHDR for landmark human study of IMP761 in autoimmune diseases Next Science\u2019s XPERIENCE proven effective: study shows zero infection rate after <a href=\"https:\/\/economicherald.net\/?p=8505\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":8506,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-8505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=8505\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"\u00a0Immutep teams up with CHDR for landmark human study of IMP761 in autoimmune diseases Next Science\u2019s XPERIENCE proven effective: study shows zero infection rate after [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=8505\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-18T03:07:47+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study\",\"datePublished\":\"2024-04-18T03:07:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505\"},\"wordCount\":473,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Immutep-teams-up-with-CHDR-for-landmark-human-study-of-IMP761-in-autoimmune-diseases.-Picture-Getty-IRpvmC.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=8505\",\"name\":\"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Immutep-teams-up-with-CHDR-for-landmark-human-study-of-IMP761-in-autoimmune-diseases.-Picture-Getty-IRpvmC.jpeg\",\"datePublished\":\"2024-04-18T03:07:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=8505\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Immutep-teams-up-with-CHDR-for-landmark-human-study-of-IMP761-in-autoimmune-diseases.-Picture-Getty-IRpvmC.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Immutep-teams-up-with-CHDR-for-landmark-human-study-of-IMP761-in-autoimmune-diseases.-Picture-Getty-IRpvmC.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8505#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=8505","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study - Economic Herald","og_description":"\u00a0Immutep teams up with CHDR for landmark human study of IMP761 in autoimmune diseases Next Science\u2019s XPERIENCE proven effective: study shows zero infection rate after [more...]","og_url":"https:\/\/economicherald.net\/?p=8505","og_site_name":"Economic Herald","article_published_time":"2024-04-18T03:07:47+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=8505#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=8505"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study","datePublished":"2024-04-18T03:07:47+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=8505"},"wordCount":473,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=8505#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Immutep-teams-up-with-CHDR-for-landmark-human-study-of-IMP761-in-autoimmune-diseases.-Picture-Getty-IRpvmC.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=8505","url":"https:\/\/economicherald.net\/?p=8505","name":"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=8505#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=8505#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Immutep-teams-up-with-CHDR-for-landmark-human-study-of-IMP761-in-autoimmune-diseases.-Picture-Getty-IRpvmC.jpeg","datePublished":"2024-04-18T03:07:47+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=8505#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=8505"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=8505#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Immutep-teams-up-with-CHDR-for-landmark-human-study-of-IMP761-in-autoimmune-diseases.-Picture-Getty-IRpvmC.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Immutep-teams-up-with-CHDR-for-landmark-human-study-of-IMP761-in-autoimmune-diseases.-Picture-Getty-IRpvmC.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=8505#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Immutep hooks leading research firm CHDR to conduct Phase 1 drug study"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/8505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8505"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/8505\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/8506"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}